首页> 外文OA文献 >Long-term disease-free survival of patients with primary cardiac lymphoma treated with systemic chemotherapy and radiotherapy
【2h】

Long-term disease-free survival of patients with primary cardiac lymphoma treated with systemic chemotherapy and radiotherapy

机译:系统性化学疗法和放射疗法治疗原发性心脏淋巴瘤患者的长期无病生存

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Primary cardiac lymphoma (PCL) is a rare disease entity with only a few reported cases in Korea. In this paper, we report a case of PCL in a 59-year-old man presenting with chest pain. Diffuse large B-cell lymphoma was diagnosed through a cardiac catheterization-assisted percutaneous endomyocardial biopsy, and there was no evidence of extracardiac involvement of the lymphoma.The patient had a complete clinical response after systemic chemotherapy with a rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen and additional post-chemotherapeutic radiation therapy. The patient experienced a long-term disease-free survival of over 4 years. However, he received coronary artery bypass graft surgery due to an acute myocardial infarction that occurred 3 years after the completion of the radiation therapy. Although the addition of radiation therapy to the treatment is thought to decrease the risk of relapse in patients with PCL, a careful and thorough consideration of the potential complications of radiation therapy, particularly with respect to cardiac complications, should be considered.
机译:原发性心脏淋巴瘤(PCL)是一种罕见的疾病,在韩国只有几例报道。在本文中,我们报告了一名59岁的男性胸痛PCL病例。经心脏导管辅助的经皮心内膜活检诊断为弥漫性大B细胞淋巴瘤,没有证据表明淋巴瘤在心外受累。在接受利妥昔单抗,环磷酰胺,阿霉素,长春新碱,和泼尼松龙(R-CHOP)方案以及其他化疗后放疗。患者经历了超过4年的长期无病生存。但是,由于放疗完成3年后发生的急性心肌梗塞,他接受了冠状动脉搭桥手术。尽管人们认为在放射治疗中增加放射治疗可降低PCL患者复发的风险,但应仔细,彻底地考虑放射治疗的潜在并发症,尤其是在心脏并发症方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号